viral
vaccin
could
consid
among
import
medic
achiev
centuri
prevent
much
suffer
save
mani
live
although
cur
antivir
drug
exist
desper
depend
effort
academ
government
industri
scientist
advanc
viral
vaccin
prevent
control
infecti
diseas
next
decad
hope
see
advanc
develop
current
investig
viral
vaccin
childhood
adult
infect
articl
review
licens
viral
vaccin
safeti
concern
advanc
develop
investig
viral
vaccin
inadequ
number
antivir
drug
avail
mani
virus
mani
avail
antivir
drug
provid
cure
infect
mere
alter
clinic
cours
diseas
therefor
prevent
infect
crucial
answer
lie
immun
educ
public
especi
individu
highest
risk
respect
viru
tabl
signific
impact
immun
viral
agent
smallpox
overst
viral
vaccin
led
notabl
decreas
infect
complic
sinc
introduct
polioviru
vaccin
polioviru
erad
western
hemispher
estim
global
erad
year
measl
vaccin
anoth
exampl
year
widespread
measl
vaccin
record
low
measl
case
report
unit
state
us
avail
viral
vaccin
also
serv
provid
basic
framework
knowledg
experi
viral
vaccin
develop
new
vaccin
need
progress
find
new
vaccin
rapid
enough
incid
mani
viral
infect
increas
despit
avail
antivir
agent
threat
bioterror
mani
virus
potenti
agent
develop
viral
vaccin
extrem
import
protect
certain
member
popul
public
health
healthcar
respons
team
laboratori
worker
work
virus
militari
personnel
risk
vaccin
must
also
consid
administr
vaccin
safeti
concern
exist
viral
vaccin
vaccin
given
consider
host
factor
age
health
statu
immunocompet
vs
immunocompromis
ill
viral
exposur
pregnant
women
allergi
prospect
vaccin
gener
take
decad
develop
mark
small
increment
advanc
final
product
becom
avail
articl
provid
review
licens
viral
vaccin
safeti
concern
recent
advanc
develop
investig
viral
vaccin
year
introduc
us
edward
jenner
first
demonstr
inocul
cowpox
viru
human
skin
could
lead
protect
subsequ
smallpox
infect
inocul
substanc
name
vaccin
base
latin
word
vacca
mean
cow
vaccin
use
smallpox
vaccin
deriv
vaccinia
viru
speci
similar
cowpox
viru
caus
smallpox
variola
viru
viru
belong
poxvirida
famili
orthopoxviru
genera
includ
vaccinia
cowpox
monkeypox
virus
smallpox
vaccin
consist
sever
strain
live
attenu
vaccinia
viru
serv
prototyp
success
viral
vaccin
prior
immun
smallpox
infect
kill
hundr
million
peopl
erad
diseas
consid
one
greatest
accomplish
medicin
recent
concern
smallpox
may
use
potenti
biolog
warfar
threat
viru
complet
elimin
renew
interest
develop
product
smallpox
vaccin
two
smallpox
vaccin
avail
futur
administ
direct
inocul
superfici
layer
skin
viru
abl
grow
induc
immunolog
respons
serv
protect
host
smallpox
dryvax
wyeth
laboratori
inc
marietta
pennsylvania
licens
immun
smallpox
public
health
healthcar
respons
team
laboratori
worker
involv
research
activ
involv
vaccinia
viru
emerg
vaccin
strategi
develop
event
smallpox
outbreak
fulfil
recommend
nation
advisori
committe
immun
practic
acip
smallpox
vaccin
prioriti
given
earli
diagnosi
case
contact
patient
sinc
onset
fever
household
member
contact
healthcar
worker
public
health
personnel
first
respond
personnel
assist
outbreak
control
measur
emerg
respons
activ
dryvax
store
lyophil
calflymph
vaccin
freez
dri
reconstitut
use
diluent
contain
glycerin
phenol
reconstitut
lyophil
undilut
vaccin
contain
million
live
vaccinia
virusml
absenc
circul
smallpox
vaccin
contraind
individu
allergi
polymyxin
b
sulfat
streptomycin
sulfat
chlortetracyclin
hydrochlorid
neomycin
sulfat
individu
allerg
symptom
compound
contact
individu
smallpox
presenc
smallpox
concurr
given
antihistamin
glucocorticoid
smallpox
vaccin
also
contraind
person
histori
presenc
eczema
atop
dermat
acut
chronic
exfoli
skin
condit
condit
associ
immunosuppress
person
infect
human
immunodefici
viru
hiv
use
topic
ocular
steroid
medic
year
age
pregnant
intend
becom
pregnant
next
week
breastfeed
eczema
vaccinatum
fig
seriou
form
dissemin
vaccinia
infect
occur
among
person
atop
dermat
dermatolog
condit
person
report
atop
dermat
dermatolog
condit
household
member
vaccin
unless
healthcar
provid
determin
rash
eczema
atop
dermat
second
smallpox
vaccin
acambisbaxt
laboatori
tissu
cultur
cell
vaccin
involv
use
two
cell
line
propag
vaccinia
viru
vero
monkey
kidney
cell
line
human
fibroblast
cell
line
tissu
cultur
cell
vaccin
develop
hope
supplant
calflymph
vaccin
extens
vaccin
program
need
vaccin
abl
elicit
humor
cellmedi
immun
greater
individu
develop
success
vaccin
defin
antibodi
titer
greater
within
week
immun
although
controversi
durat
immun
smallpox
vaccin
two
studi
shown
vaccin
protect
durat
year
residu
immun
may
last
year
greater
person
undergon
revaccin
smallpox
volunt
vaccin
smallpox
year
ago
substanti
humor
cellular
immun
vaccinia
persist
wherea
antivir
tcell
respons
declin
slowli
halflif
year
individu
undergo
postexposur
vaccin
receiv
smallpox
vaccin
within
day
exposur
postvaccin
may
prevent
natur
histori
diseas
alter
sever
diseas
provid
protect
mortal
epidemiolog
evid
suggest
postexposur
vaccin
done
day
third
smallpox
vaccin
develop
modifi
vaccinia
ankara
mva
deriv
ankara
vaccinia
strain
one
highli
attenu
strain
passag
chicken
embryo
fibroblast
host
restrict
unabl
replic
human
mammalian
cell
mva
develop
serv
attenu
smallpox
vaccin
primari
vaccin
person
resid
region
smallpox
endem
advantag
mva
lie
safeti
profil
advers
reaction
observ
clinic
trial
person
high
risk
skin
lesion
vaccin
safe
use
vaccin
person
turkey
germani
howev
effect
smallpox
unknown
smallpox
vaccin
gener
safe
effect
prevent
smallpox
base
seri
studi
conduct
estim
frequenc
advers
event
associ
smallpox
vaccin
among
adult
year
age
older
reanalyz
includ
gener
rash
per
one
million
primari
vaccine
eczema
vaccinatum
per
one
million
primari
vaccine
vaccinia
necrosum
per
one
million
primari
vaccine
postvaccini
enceph
four
per
one
million
primari
vaccine
death
five
per
one
million
primari
vaccine
ocular
vaccinia
fig
may
also
occur
secondari
autoinocul
myocard
increasingli
report
administr
new
york
citi
board
health
nycboh
smallpox
vaccinia
strain
among
us
militari
occur
per
primari
vaccine
time
unvaccin
personnel
data
contrast
older
finnish
data
suggest
myocard
occur
everi
militari
recruit
vaccin
nonnycboh
vaccinia
strain
european
union
set
rapid
alert
system
biolog
chemic
attack
european
nation
smallpox
vaccin
stockpil
develop
countri
made
almost
prepar
unit
kingdom
decid
use
lister
elstre
strain
smallpox
vaccin
powderject
oxford
uk
buy
vaccin
bavarian
nordic
copenhagen
denmark
munich
germani
seed
viru
commonli
use
produc
vaccin
worldwid
smallpox
erad
campaign
compar
mva
gold
standard
recombin
vaccinia
virus
lister
elstre
strain
compar
favor
term
safeti
immunogen
dutch
ministri
health
set
april
conting
deadlin
mass
smallpox
vaccin
countri
diseas
control
centr
felt
ring
vaccin
best
option
mass
vaccin
implement
ring
vaccin
entail
isol
confirm
suspect
case
smallpox
vaccin
peopl
specif
area
anyon
come
within
infect
person
mani
overlap
ring
ring
vaccin
fail
mass
vaccin
could
follow
dutch
institut
public
health
environ
alreadi
manufactur
million
smallpox
vaccin
inactiv
influenza
vaccin
consist
three
viru
strain
gener
two
type
one
type
b
vaccin
feder
drug
administr
fda
approv
prepar
year
base
virus
like
circul
region
world
vaccin
viru
grown
embryon
hen
egg
purifi
inactiv
trival
inactiv
vaccin
current
avail
subvirion
split
purifi
surfac
antigen
subunit
whole
viru
prepar
whole
viru
influenza
vaccin
given
children
year
age
due
increas
potenti
febril
reaction
children
young
adult
receiv
influenza
vaccin
develop
high
level
antibodi
titer
person
chronic
diseas
elderli
may
develop
lower
immun
respons
remain
suscept
infect
howev
vaccin
individu
shown
decreas
risk
complic
hospit
death
children
young
adult
influenza
vaccin
effect
prevent
influenza
control
trial
good
match
vaccin
circul
influenza
strain
studi
vaccin
lowrisk
elderli
person
demonstr
efficaci
prevent
laboratoryconfirm
influenza
studi
elderli
nurs
home
resid
influenza
vaccin
effect
prevent
influenza
ill
also
effect
prevent
pneumonia
hospit
effect
prevent
death
immun
follow
influenza
vaccin
begin
within
week
rare
persist
beyond
year
protect
antibodi
level
may
last
month
less
certain
elderli
patient
addit
strain
influenza
may
differ
significantli
one
season
next
thu
increas
need
annual
vaccin
influenza
immun
indic
individu
month
age
increas
risk
complic
influenza
contact
individu
ie
caregiv
medic
personnel
earli
flu
season
unit
state
increas
report
morbid
associ
influenza
paediatr
popul
acip
updat
recommend
includ
focu
children
includ
month
age
young
otherwis
healthi
children
increas
risk
influenzarel
hospit
studi
suggest
use
influenza
vaccin
among
children
cost
save
like
acip
recommend
univers
immun
children
near
futur
atrisk
popul
includ
person
year
age
resid
nurs
home
chronic
pulmonari
cardiovascular
disord
person
hiv
vaccin
also
indic
individu
desir
decreas
risk
influenza
infect
immun
regimen
consist
one
dose
given
year
septemb
midnovemb
administr
vaccin
still
recommend
midnovemb
influenza
activ
peak
commun
previous
unvaccin
children
year
age
receiv
two
vaccin
dose
least
month
apart
develop
suffici
antibodi
level
local
reaction
advers
effect
influenza
vaccin
may
includ
fever
malais
headach
arthralgia
myalgia
symptom
typic
begin
within
h
persist
day
one
clinic
trial
incid
advers
effect
differ
vaccin
group
placebo
syndrom
gb
associ
influenza
vaccin
significantli
greater
frequenc
gb
found
swine
influenza
vaccin
recent
investig
show
extrem
small
risk
gb
current
vaccin
slightli
one
extra
case
per
million
vaccine
immedi
allerg
reaction
hive
angioedema
system
anaphylaxi
rare
occur
influenza
vaccin
hypersensit
reaction
like
due
residu
egg
protein
exposur
sensit
patient
major
eggallerg
subject
safe
receiv
immun
histori
anaphylact
reaction
egg
previou
influenza
vaccin
discuss
histori
allergi
physician
decis
made
regard
vaccin
promis
new
intranas
vaccin
approv
fda
altern
form
influenza
vaccin
coldadapt
live
attenu
trival
influenza
viru
vaccin
flumist
abl
replic
cooler
nasal
passag
stimul
mucos
well
system
immun
similar
natur
infect
howev
alter
viru
unabl
grow
warmer
temperatur
lower
respiratori
tract
placebo
control
clinic
studi
children
month
age
shown
vaccin
effect
prevent
cultureposit
influenza
b
infect
also
vaccin
group
fewer
febril
ill
fewer
case
febril
otiti
media
compar
placebo
advers
reaction
mild
includ
rhinorrhoea
fever
lethargi
similar
studi
adult
demonstr
fewer
day
sever
febril
ill
fever
day
febril
upper
respiratori
tract
ill
result
fewer
miss
work
day
fewer
physician
visit
needlefre
vaccin
conveni
administ
recommend
prevent
influenza
healthi
peopl
year
age
disadvantag
flumist
cost
least
per
dose
cover
medicar
insur
plan
compar
inactiv
influenza
vaccin
usual
cost
per
dose
cover
medicar
part
b
medicaid
insur
plan
healthi
individu
age
year
administ
singl
dose
annual
winter
children
age
year
recommend
two
dose
first
year
immun
coldadapt
trival
influenza
vaccin
ensur
protect
strain
contain
vaccin
thereaft
singl
annual
revaccin
child
suffici
switzerland
licens
inactiv
virosomalsubunit
influenza
vaccin
nasalflu
berna
biotech
contain
escherichia
coli
heatlabil
toxin
mucos
adjuv
exist
four
winter
season
seriou
advers
event
report
prelicensur
trial
conduct
among
volunt
compar
parenter
vaccin
intranas
vaccin
associ
significantli
increas
risk
bell
palsi
adjust
odd
ratio
confid
interv
time
risk
control
correspond
excess
case
per
vaccin
found
period
highest
risk
day
vaccin
vaccin
sinc
taken
market
mention
bell
palsi
report
flumist
anoth
intranas
influenza
vaccin
europ
new
influenza
subunit
vaccin
name
fluad
shown
immunogen
howev
vaccin
caus
significantli
higher
rate
transient
mild
local
reaction
compar
convent
subunit
vaccin
inactiv
split
virion
influenza
vaccin
name
vaxigrip
given
children
adult
elderli
shown
safe
immunogen
recommend
influenza
season
vaccin
contain
three
strain
abeij
b
random
control
trial
compar
two
vaccin
total
subject
subject
receiv
fluad
experienc
local
reaction
compar
vaxigrip
group
vaccin
immunogen
three
strain
influenza
subject
year
age
older
fluad
immunogen
vaxigrip
three
viru
strain
conclus
consist
metaanalysi
trial
elderli
subject
show
greater
immun
respons
adjuv
vaccin
compar
nonadjuv
subunit
split
vaccin
yellow
fever
consid
origin
viral
haemorrhag
fever
although
individu
experi
mild
ill
approxim
infect
person
develop
seriou
diseas
hepatoren
dysfunct
myocardi
injuri
haemorrhag
twenti
percent
seriou
infect
yellow
fever
result
death
incid
yellow
fever
increas
dramat
past
two
decad
case
death
report
although
mani
case
believ
go
unreport
yellow
fever
found
tropic
south
america
subsaharan
africa
two
clinic
ident
form
yellow
fever
existurban
jungl
urban
form
transmit
human
human
aed
aegypti
mosquito
jungl
form
transmit
among
nonhuman
primat
variou
mosquito
human
incident
infect
live
attenu
yellow
fever
vaccin
fda
approv
produc
grow
viru
strain
chick
embryo
seroconvers
rate
vaccin
adult
children
immun
document
least
year
thought
lifelong
regardless
certif
yellow
fever
immun
intern
travel
certain
countri
valid
year
requir
revaccin
thereaft
immun
yellow
fever
indic
anyon
month
age
live
travel
endem
area
tropic
south
america
subsaharan
africa
vaccin
may
also
requir
entri
particular
countri
current
inform
avail
health
depart
yellow
fever
vaccin
known
extrem
safe
side
effect
two
percent
vaccin
recipi
may
develop
lowgrad
fever
mild
headach
myalgia
mild
symptom
gener
last
day
immedi
hypersensit
reaction
report
less
one
per
one
million
vaccin
dose
affect
vaccine
typic
develop
rash
urticaria
andor
asthma
symptom
usual
histori
egg
allergi
greater
million
vaccin
dose
worldwid
case
enceph
yellow
fever
vaccin
report
major
case
occur
children
month
age
prompt
recommend
delay
vaccin
month
age
concern
yellow
fever
vaccin
report
person
advanc
age
center
diseas
control
prevent
cdc
notifi
sever
ill
one
death
elderli
us
resid
tempor
associ
yellow
fever
vaccin
rate
report
advers
event
among
elderli
vaccine
found
higher
vaccine
year
age
recommend
elderli
travel
includ
balanc
risk
sever
ill
death
due
yellow
fever
infect
risk
system
ill
due
yellow
fever
vaccin
yellow
fever
immun
withheld
pregnant
women
immunosuppress
individu
us
asymptomat
infect
hiv
consid
contraind
sinc
introduct
widespread
use
two
polio
vaccin
number
polioviru
infect
complic
dramat
decreas
western
hemispher
certifi
free
indigen
wild
polioviru
last
case
indigen
acquir
wild
polioviru
infect
us
occur
sinc
time
averag
case
paralyt
polio
report
year
us
due
use
oral
live
attenu
polio
vaccin
opv
vaccineassoci
paralyt
poliomyel
vapp
occur
one
case
per
million
dose
common
first
vaccin
dose
one
case
per
first
opv
dose
vapp
believ
occur
mutat
revers
vaccin
viru
neurotrop
form
mutat
virus
call
revert
believ
occur
almost
vaccin
recipi
rare
result
paralyt
diseas
vapp
result
ident
caus
wild
viru
may
perman
world
health
organ
certifi
europ
free
poliomyel
last
european
case
indigen
wild
poliomyel
occur
eastern
turkey
unvaccin
boy
paralyz
viru
howev
polioviru
import
polioendem
countri
continu
risk
develop
strategi
global
erad
poliomyel
end
year
unfortun
met
signific
progress
achiev
toward
goal
reduct
poliomyel
case
polioviru
found
everi
contin
australia
howev
three
major
foci
diseas
remain
includ
region
south
asia
west
africa
central
africa
inactiv
polioviru
vaccin
ipv
develop
jona
salk
earli
introduc
use
us
although
vaccin
shown
safe
efficaci
use
quickli
declin
introduct
opv
earli
enhanc
version
inactiv
vaccin
develop
later
licens
us
potent
formul
result
improv
immun
children
adult
children
given
three
dose
regimen
develop
antibodi
respons
three
type
polioviru
month
receiv
second
dose
signific
increas
antibodi
concentr
observ
administr
third
dose
separ
clinic
studi
subject
develop
protect
antibodi
three
dose
although
use
ipv
result
less
gastrointestin
immun
opv
variou
combin
two
polioviru
shown
provid
optim
gastrointestin
immun
durat
immun
induc
ipv
unknown
thought
longterm
studi
sweden
use
four
dose
less
potent
ipv
indic
vaccin
recipi
persist
antibodi
year
opv
first
licens
us
opv
consist
live
attenu
strain
three
serotyp
polioviru
grown
monkey
kidney
cell
cultur
opv
quickli
becam
favor
vaccin
eas
oral
administr
consist
product
gastrointestin
immun
expect
longlast
immun
spread
vaccin
viru
unvaccin
contact
three
dose
opv
recipi
produc
immun
three
serotyp
polioviru
immun
consid
long
last
like
lifelong
fecal
shed
vaccin
viru
opv
administr
vaccin
immun
unvaccin
contact
howev
viral
shed
mutat
viru
may
also
lead
vapp
unvaccin
contact
particularli
immunosuppress
risk
vapp
almost
time
higher
person
certain
type
immunodefici
particularli
b
lymphocyt
disord
reduc
synthesi
immun
globulin
condit
case
vapp
report
us
fortynin
case
occur
healthi
vaccin
recipi
forti
case
develop
healthi
contact
vaccin
recipi
twentythre
case
occur
immunodefici
vaccine
seven
case
develop
immunodefici
contact
vaccin
recipi
remain
six
case
develop
commun
contact
vapp
occur
frequent
adult
immunodefici
person
receiv
first
dose
opv
diminish
risk
wild
polioviru
diseas
us
risk
vapp
consid
less
accept
recommend
elimin
risk
vapp
allipv
schedul
use
routin
childhood
vaccin
unit
state
children
receiv
four
dose
ipv
age
month
age
month
age
month
age
year
opv
avail
may
use
follow
special
circumst
mass
vaccin
campaign
control
outbreak
paralyt
polio
unvaccin
children
travel
within
week
area
polio
endem
epidem
children
parent
accept
recommend
number
vaccin
inject
children
may
receiv
opv
third
fourth
dose
situat
healthcar
provid
administ
opv
discuss
risk
vapp
parent
caregiv
result
opv
suppli
expect
limit
unit
state
inventori
deplet
seriou
advers
effect
report
ipv
vaccin
contain
trace
amount
polymyxin
b
neomycin
streptomycin
may
caus
hypersensit
reaction
person
allerg
substanc
opv
seriou
advers
effect
vapp
evid
indic
neither
opv
ipv
increas
risk
guillain
syndrom
gb
combin
measl
mump
rubella
mmr
live
viru
vaccin
measl
mump
rubella
introduc
annual
report
case
infect
declin
declin
larg
attribut
recommend
state
implement
two
dose
mmr
vaccin
requir
children
enter
school
cdc
suggest
vaccin
first
mmr
dose
month
second
dose
year
age
immun
produc
mild
subclin
infect
noncommunic
live
attenu
virus
recommend
pregnant
women
women
consid
concept
within
next
month
immun
contraind
immunosuppress
individu
asymptomat
hiv
person
mild
immunosuppress
may
still
consid
vaccin
mmr
ultim
patient
healthcar
provid
determin
degre
immunosuppress
base
patient
sever
condit
laboratori
assess
treatment
whether
patient
abl
receiv
mmr
anoth
contraind
mmr
includ
individu
histori
anaphylact
hypersensit
neomycin
healthi
individu
minor
ill
without
fever
person
allergi
egg
exclud
receiv
vaccin
person
histori
allergi
egg
risk
sever
anaphylact
reaction
exceedingli
low
patient
observ
min
immun
possibl
advers
event
safeti
issu
mmr
question
especi
possibl
link
use
vaccin
autism
studi
wakefield
colleagu
found
eight
children
chronic
enterocol
onset
regress
development
disord
mostli
autism
administr
mmr
vaccin
studi
howev
number
limit
case
provid
gener
healthi
control
children
provid
comparison
identif
time
period
case
identifi
inabl
reproduc
result
other
respons
concern
mmr
vaccin
cdc
nation
institut
health
ask
nation
academi
sciencesinstitut
medicin
iom
establish
independ
expert
committe
review
hypothes
exist
emerg
immun
safeti
concern
conclus
committe
vast
major
case
autism
could
caus
mmr
vaccin
sinc
report
number
epidemiolog
studi
shown
lack
associ
administr
mmr
vaccin
autism
committe
conclud
need
review
exist
recommend
univers
use
mmr
month
age
year
age
committe
conclus
uphold
current
polici
give
mmr
vaccin
one
instead
three
separ
inject
europ
three
major
mmr
vaccin
vac
tripl
msd
aventi
pasteur
msd
contain
ender
edmonston
hyperattenu
measl
jeryllynn
mump
wistar
ra
rubella
triviraten
berna
contain
schwarz
deriv
jeryl
lynn
wistar
ra
priorix
glaxo
smithklin
contain
edmonstonzagreb
rubini
mump
wistar
ra
jeryl
lynn
strain
use
vac
tripl
msd
util
industri
countri
triviraten
vaccin
wide
util
variou
european
nation
countri
report
sporad
outbreak
mump
attribut
failur
rubini
strain
confer
protect
measl
measl
effici
transmiss
rate
earli
epidemiolog
studi
estim
case
measl
could
caus
suscept
famili
contact
develop
diseas
first
measl
vaccin
licens
develop
univers
childhood
immun
us
incid
measl
decreas
greater
measl
longer
consid
indigen
diseas
countri
record
low
case
measl
confirm
even
encourag
result
lack
complianc
routin
mmr
vaccin
us
remain
problemat
greater
one
million
children
die
measl
year
develop
countri
measl
vaccin
attenu
version
previou
endersedmonston
viru
strain
fewer
advers
reaction
occur
attenu
version
measl
vaccin
produc
cultur
moraten
viru
strain
chick
embryo
cell
measl
vaccin
produc
humor
cellular
immun
respons
receiv
two
dose
mmr
vaccin
recipi
develop
serolog
evid
immun
measl
immun
believ
lifelong
similar
acquir
infect
wildtyp
viru
although
extrem
rare
measl
infect
report
patient
previous
document
postimmun
seroconvers
epidem
measl
case
found
occur
among
unvaccin
children
much
less
frequent
vaccin
children
mostli
children
year
age
vaccin
children
receiv
one
dose
alway
protect
measl
thu
lead
recommend
second
dose
children
age
year
age
ensur
protect
children
develop
immun
first
dose
sinc
sporad
outbreak
measl
occur
popul
refus
vaccin
receiv
one
dose
measl
vaccin
includ
commun
utah
nevada
christian
scientist
school
missouri
illinoi
adult
student
commun
advers
effect
measl
vaccin
includ
fever
transient
viral
exanthem
less
commonli
enceph
encephalopathi
less
one
per
one
million
vaccin
small
number
report
describ
occurr
subacut
scleros
pancenceph
sspe
person
histori
vaccin
known
histori
infect
care
review
individu
suggest
case
unrecogn
natur
measl
infect
prior
vaccin
sspe
directli
relat
infect
gener
thought
widespread
use
mmr
vaccin
sspe
elimin
us
live
measl
vaccin
increas
risk
complic
live
attenu
mump
vaccin
first
introduc
decreas
case
mump
report
lowest
annual
total
ever
report
children
adolesc
adult
receiv
two
dose
mmr
vaccin
annual
incid
mump
steadili
decreas
europ
larg
serolog
survey
mump
six
countri
denmark
england
wale
franc
germani
itali
netherland
conduct
show
low
incid
diseas
mump
vaccin
coverag
high
eg
netherland
high
incid
diseas
countri
vaccin
coverag
poor
eg
itali
children
adult
born
later
medic
contraind
receiv
mmr
vaccin
unless
document
immun
serolog
evid
immun
measl
mump
rubella
children
receiv
mump
vaccin
part
mmr
least
month
age
howev
second
dose
mmr
gener
consid
booster
dose
primari
immun
respons
first
dose
provid
longterm
protect
develop
mump
person
born
gener
consid
immun
mump
mump
vaccin
jeryllynn
strain
prepar
chick
embryo
cell
cultur
clinic
efficaci
studi
shown
children
adult
develop
serolog
evid
immun
vaccin
lower
protect
rate
rang
report
outbreak
studi
serolog
epidemiolog
evid
suggest
immun
persist
least
year
immun
advers
reaction
mump
vaccin
includ
lowgrad
fever
mild
parot
viral
exanthema
advers
neurolog
effect
extrem
rare
causal
associ
mump
vaccin
unvaccin
individu
infect
rubella
signific
morbid
mortal
largest
annual
total
case
rubella
congenit
rubella
syndrom
cataract
congenit
heart
diseas
loss
hear
hepatosplenomegali
jaundic
microcephali
development
delay
occur
us
case
report
case
per
popul
follow
vaccin
licensur
rubella
incid
fell
rapidli
fewer
case
per
year
report
case
per
popul
record
low
annual
total
case
rubella
report
similar
mump
vaccin
least
one
dose
rubella
vaccin
combin
mmr
vaccin
routin
recommend
children
adult
born
later
two
differ
live
attenu
rubella
vaccin
strain
cendehil
initi
develop
licens
us
two
vaccin
strain
replac
ra
rubella
abortu
explant
vaccin
grown
human
diploid
fibroblast
cell
cultur
nasal
antibodi
higher
serum
antibodi
titer
persist
ra
vaccin
vaccin
induc
antibodi
respons
recipi
immun
thought
lifelong
shown
persist
least
year
ra
also
associ
fewer
advers
event
compar
previou
rubella
vaccin
advers
effect
rubella
vaccin
includ
fever
lymphadenopathi
viral
exanthema
typic
day
vaccin
arthralgia
arthriti
occur
commonli
adult
vaccin
especi
women
joint
symptom
less
common
children
adult
children
joint
symptom
typic
begin
within
first
week
vaccin
remit
within
day
although
joint
may
affect
knee
finger
frequent
involv
loui
pasteur
develop
first
vaccin
postexposur
treatment
rabi
sever
rabi
vaccin
follow
contain
brain
nerv
tissu
pose
seriou
risk
neurolog
complic
addit
vaccin
led
pathogen
infect
incomplet
inactiv
vaccin
viru
safer
duck
embryo
vaccin
later
introduc
prove
less
immunogen
year
develop
studi
cell
culturederiv
vaccin
becom
gold
standard
rabi
immun
human
diploid
cell
vaccin
hdcv
licens
us
contain
concentr
purifi
inactiv
rabi
viru
pitmanmoor
strain
compar
previou
rabi
vaccin
hdcv
induc
higher
level
antibodi
respons
earlier
time
multipl
studi
shown
hdcv
effect
preexposur
postexposur
immun
sever
clinic
studi
rabi
vaccin
regimen
pre
postexposur
prophylaxi
subject
develop
antibodi
respons
within
week
antibodi
respons
typic
develop
within
day
last
least
year
preexposur
prophylaxi
intend
high
risk
contract
rabi
bite
carnivor
wild
anim
bat
bite
dog
cat
develop
symptom
day
observ
rabid
suspect
rabid
unknown
ie
escap
bite
unprovok
attack
given
three
dose
day
cdc
recommend
postexposur
prophylaxi
given
expos
suspect
confirm
rabid
anim
regimen
given
conjunct
rabi
immun
globulin
consist
five
vaccin
given
day
previous
immun
individu
expos
rabid
anim
requir
vaccin
given
two
dose
day
apart
booster
recommend
person
frequent
exposur
rabi
viru
ie
person
work
research
laboratori
vaccin
product
rabi
viru
highest
risk
inappar
occup
exposur
person
serum
sampl
submit
antibodi
test
everi
month
administ
booster
maintain
complet
neutral
serum
dilut
rapid
fluoresc
focu
inhibit
test
rffit
individu
frequent
risk
ie
veterinarian
staff
anim
control
wildlif
offic
spelunk
serum
sampl
everi
year
administ
booster
maintain
complet
neutral
serum
dilut
rffit
low
frequenc
exposur
requir
routin
preexposur
booster
complet
primari
preexposur
vaccin
advers
reaction
less
common
hdcv
compar
previous
avail
rabi
vaccin
twenti
percent
recipi
report
mild
system
effect
nausea
abdomin
pain
headach
dizzi
muscl
ach
system
allerg
reaction
hive
anaphylact
shock
rare
report
neurolog
complic
includ
three
case
gb
rare
report
approxim
individu
receiv
booster
dose
hdcv
develop
immun
complexlik
reaction
day
follow
case
character
gener
urticaria
may
includ
angioedema
nausea
vomit
fever
malais
arthralgia
arthriti
reaction
associ
presenc
betapropiolacton
alter
human
albumin
contain
hdcv
high
cost
associ
hdcv
develop
cell
cultur
vaccin
pursu
purifi
chick
embryo
cell
cultur
vaccin
pcecv
licens
us
prophylact
postexposur
immun
vaccin
produc
growth
fix
rabi
viru
strain
fluri
lep
chicken
embryo
fibroblast
cultur
clinic
studi
shown
effect
welltoler
hdcv
antibodi
respons
recipi
compar
hdcv
type
iii
hypersensit
reaction
observ
pcecv
seriou
anaphylact
reaction
neuroparalyt
event
report
rabi
vaccin
absorb
rva
anoth
avail
rabi
vaccin
produc
growth
kissl
strain
challeng
viru
standard
rabi
viru
fetal
rhesu
lung
diploid
cell
cultur
three
type
inactiv
rabi
vaccin
consid
compar
safeti
efficaci
prior
develop
hepat
b
vaccin
annual
incid
individu
infect
hbv
us
estim
plasmaderiv
hepat
b
vaccin
licens
us
vaccin
highli
effect
induc
immun
limit
exist
larg
scale
product
feasibl
limit
suppli
suitabl
carrier
plasma
despit
chemic
treatment
plasma
product
safeti
also
concern
risk
albeit
small
hiv
transmiss
issu
address
licensur
yeast
recombin
hepat
b
vaccin
vaccin
first
ever
licens
recombin
viral
vaccin
prototyp
well
first
effect
viral
vaccin
sexual
transmit
diseas
vaccin
produc
recombin
dna
technolog
insert
gene
hepat
b
surfac
antigen
yeast
saccharomyc
cerevisia
baker
yeast
highrisk
homosexu
men
clinic
studi
demonstr
threedos
vaccin
efficaci
prevent
acut
hepat
b
approxim
immunocompet
adult
develop
signific
antibodi
titer
three
dose
hepat
b
vaccin
nearli
children
respond
vaccin
level
durat
protect
decreas
advanc
age
age
acquir
immun
factor
associ
lower
likelihood
seroconvers
includ
immunosuppress
renal
failur
prematur
low
birth
weight
age
older
year
obes
smoke
specif
individu
annual
antibodi
test
assess
booster
dose
administ
person
antihb
level
miuml
altern
deliveri
system
adenoviru
vaccinia
viru
adjuv
sever
differ
type
vaccin
dna
vaccin
pre
vaccin
evalu
hope
find
way
increas
immunogen
hepat
b
vaccin
especi
import
popul
lower
rate
seroconvers
studi
avail
durat
immun
afford
hepat
b
vaccin
avail
studi
suggest
longterm
efficaci
expect
first
year
vaccin
antibodi
level
declin
rapidli
thereaft
antibodi
level
declin
slower
pace
loss
detect
antibodi
hepat
b
year
vaccin
necessarili
indic
lack
immun
major
individu
protect
immunolog
memori
b
lymphocyt
mount
anamnest
respons
natur
infect
howev
case
report
individu
develop
hepat
b
infect
previous
vaccin
individu
gener
subclin
diseas
none
develop
chronic
infect
seriou
complic
hepat
b
vaccin
includ
three
dose
given
month
vaccin
recommend
person
live
travel
area
high
endem
hepat
b
healthcar
personnel
mortician
person
engag
high
risk
sexual
activ
person
chronic
liver
diseas
due
caus
hepat
b
prison
user
illicit
inject
drug
polic
fire
depart
personnel
render
first
aid
children
age
year
widespread
use
children
thimerosalfre
vaccin
recent
approv
fda
thimeros
mercurycontain
preserv
prompt
limit
use
children
postexposur
prophylaxi
unvaccin
person
exposur
person
acut
hepat
b
eg
sexual
contact
follow
needlestick
splash
accid
birth
neonat
hbsagpost
women
administ
hepat
b
vaccin
unvaccin
vaccin
expos
person
hepat
b
immunoglobulin
given
soon
possibl
hepat
b
antigen
antibodi
level
check
within
month
exposur
postexposur
prophylaxi
lead
increas
surviv
decreas
serolog
recurr
advers
effect
hepat
b
vaccin
gener
mild
welltoler
common
effect
includ
fatigu
headach
fever
postmarket
clinic
surveil
million
dose
hepat
b
vaccin
year
reveal
seriou
sever
reaction
attribut
vaccin
largescal
hepat
b
vaccin
program
unabl
establish
associ
vaccin
sever
advers
effect
rare
episod
anaphylaxi
rare
report
individu
develop
thrombocytopen
purpura
vascul
rheumatoid
arthriti
lichen
planu
lichenoid
reaction
howev
condit
occur
higher
rate
unvaccin
popul
report
causal
relationship
hepat
b
vaccin
varieti
autoimmun
diseas
disproven
vaccin
increas
risk
multipl
sclerosi
caus
relaps
preexist
multipl
sclerosi
twinrix
new
combin
vaccin
protect
peopl
least
year
age
hepat
hepat
b
viru
vaccin
fda
licens
may
combin
two
alreadi
approv
vaccin
havrix
engerixb
person
high
risk
exposur
virus
immun
time
advantag
vaccin
reduc
number
inject
vaccin
administ
month
preliminari
data
clinic
trial
indic
vaccine
develop
seroconvers
hepat
viru
hepat
b
surfac
antigen
persist
year
glaxosmithklin
biolog
unpublish
data
advers
effect
vaccin
similar
type
frequenc
monoval
hepat
hepat
b
vaccin
ambirix
combin
hepat
b
vaccin
contain
purifi
inactiv
strain
hepat
viru
recombin
yeastderiv
hepat
b
surfac
antigen
use
europ
openlabel
studi
shown
safe
immunogen
administ
month
children
age
year
compar
twinrix
ambirix
elicit
similar
reactogen
immunogen
profil
healthi
adolesc
reduct
number
dose
current
three
dose
schedul
make
vaccin
hepat
b
conveni
patient
reduc
healthcar
staff
time
may
lower
overal
vaccin
cost
openlabel
random
studi
show
ambirix
given
either
month
vs
month
result
similar
reactogen
immunogen
profil
year
old
healthi
adolesc
japanes
enceph
endem
arbovir
infect
transmit
variou
culex
mosquito
part
asia
although
major
infect
subclin
infect
caus
averag
report
case
death
year
one
infect
lead
symptomat
diseas
result
enceph
typic
sever
case
fatal
rate
residu
neurolog
sequela
evid
case
inactiv
japanes
enceph
viru
vaccin
develop
sever
decad
ago
licens
us
person
year
age
sinc
risk
shortterm
tourist
busi
travel
low
vaccin
recommend
travel
asia
spend
month
longer
endem
area
transmiss
season
viru
vari
accord
geograph
region
case
japanes
enceph
worldwid
report
case
mani
travel
militari
personnel
resid
asia
month
ten
percent
vaccin
develop
system
side
effect
includ
fever
headach
malais
chill
dizzi
rash
myalgia
abdomin
pain
nauseavomit
advers
neurolog
event
enceph
peripher
neuropathi
occur
one
case
per
one
million
vaccin
therefor
day
period
follow
vaccin
recommend
travel
crowd
live
area
poor
sanit
reason
develop
hepat
especi
develop
world
epidemiolgo
studi
show
nonimmun
person
incid
hepat
three
case
per
individu
resid
endem
area
high
per
individu
face
unfavor
hygien
situat
eg
backpack
aid
worker
remot
area
missionari
expert
agre
travel
visit
endem
area
vaccin
region
includ
africa
asia
except
japan
singapor
caribbean
mexican
border
remot
part
eastern
europ
hepat
vaccin
licens
also
consid
includ
routin
childhood
immun
due
children
experienc
asymptomat
mild
infect
recommend
univers
immun
children
hepat
current
implement
two
inactiv
hepat
vaccin
havrix
vaqta
licens
avail
us
vaccin
propag
human
diploid
fibroblast
cultur
inactiv
formalin
vaccin
administ
two
dose
given
month
apart
adult
children
year
older
inactiv
vaccin
show
excel
well
compar
immunogen
efficaci
rate
recipi
develop
protect
level
antibodi
within
month
first
dose
recipi
protect
month
second
dose
placebocontrol
clinic
trial
thailand
high
rate
hepat
two
dose
inactiv
hepat
vaccin
effect
protect
hepat
infect
similar
studi
show
efficaci
children
new
york
singl
dose
vaccin
limit
longterm
data
durat
immun
yet
determin
vaccin
studi
use
three
dose
seri
adult
detect
antibodi
found
subject
year
immun
kinet
model
antibodi
concentr
declin
estim
protect
level
hepat
antibodi
expect
persist
year
like
year
mathemat
evalu
longterm
immun
primari
booster
dose
hepat
calcul
protect
antibodi
level
persist
year
author
believ
immun
persist
beyond
loss
detect
antibodi
level
occur
hepat
b
immun
view
howev
valid
epax
aluminiumfre
virosomeformul
hepat
vaccin
europ
virosom
safe
effici
easili
prepar
carrier
system
small
virion
hepat
viru
surfac
virosom
contain
hemagglutinin
antigen
influenza
viru
augment
immun
respons
inactiv
hepat
viru
given
month
epax
shown
safe
well
toler
highli
immunogen
adult
children
infant
greater
month
age
epax
may
better
option
havrix
infant
studi
shown
infant
administ
havrix
either
respons
late
respons
vaccin
patient
receiv
second
dose
vaccin
month
first
shown
loss
immunogen
adult
protect
hepat
viru
two
dose
epax
estim
least
year
recommend
use
hepat
vaccin
includ
person
least
year
age
live
travel
area
high
endem
hepat
person
chronic
liver
diseas
due
caus
hepat
person
engag
high
risk
sexual
activ
resid
commun
experienc
outbreak
hepat
user
illicit
inject
drug
routin
paediatr
use
state
region
limit
data
exist
use
vaccin
postexposur
prophylaxi
immunoglobulin
offer
immedi
protect
approxim
recipi
immunoglobulin
may
diminish
antibodi
respons
live
vaccin
therefor
live
vaccin
administ
day
greater
week
immunoglobulin
administr
immunoglobulin
may
also
consid
travel
high
risk
area
within
week
initi
dose
hepat
vaccin
sinc
protect
may
complet
week
administr
hepat
vaccin
seriou
side
effect
attribut
hepat
vaccin
clinic
trial
mild
advers
effect
occur
effect
includ
sore
inject
site
adult
children
adult
headach
malais
occur
commonli
children
vaccin
associ
feed
problem
headach
prior
widespread
use
varicella
vaccin
annual
us
figur
varicella
infect
includ
approxim
million
case
hospit
death
annual
incid
varicella
today
decreas
markedli
sinc
introduct
vaccin
varicella
vaccin
develop
takahashi
approv
liveattenu
oka
strain
vaccin
vaccin
shown
safe
effect
suscept
children
least
month
age
year
receiv
varicella
vaccin
varicella
vaccin
recommend
part
routin
childhood
immun
schedul
month
age
acip
recommend
varicella
vaccin
suscept
children
least
month
old
prevent
diseas
due
transmiss
varicella
healthcar
worker
unknown
immun
statu
varicella
zoster
vaccin
screen
serolog
test
immun
found
seroneg
varicella
zoster
viru
vzv
geriatr
popul
studi
shown
restor
vzv
cellmedi
immun
administr
liveattenu
varicella
vaccin
last
year
vaccin
variou
studi
report
serum
antivzv
antibodi
concentr
product
interferongamma
increas
follow
vaccin
studi
like
enhanc
cellmedi
immun
respons
elderli
individu
vaccin
liveattenu
varicella
vaccin
protect
popul
herp
zoster
attenu
complic
larg
placebo
controlledclin
trial
underway
examin
potenti
efficaci
vaccin
geriatr
popul
varicella
zoster
vaccin
develop
japan
attenu
viru
isol
vesicular
fluid
healthi
boy
surnam
oka
natur
varicella
infect
clinic
studi
live
attenu
oka
strain
vaccin
show
seroconvers
rate
week
vaccin
advers
reaction
longterm
followup
studi
shown
protect
chickenpox
least
year
subject
continu
persist
antibodi
delayedtyp
skin
reaction
varicellazost
antigen
doubleblind
placebocontrol
studi
oka
vaccin
us
children
varicella
vaccin
shown
efficaci
month
followup
subject
remain
free
clinic
diseas
chickenpox
studi
shown
oka
vaccin
induc
humor
cellmedi
immun
healthi
children
protect
least
year
studi
suggest
effect
decreas
significantli
year
post
vaccin
delayedtyp
hypersensit
skin
reaction
varicellazost
viru
antigen
shown
occur
least
year
vaccin
case
seri
studi
demonstr
less
sever
varicella
ie
afebril
lesion
shorter
durat
ill
vaccin
person
unvaccin
children
oka
vaccin
given
singl
dose
month
year
age
individu
age
receiv
two
dose
week
apart
durat
protect
unknown
time
need
booster
immun
uncertain
observ
vaccine
expos
natur
varicella
boost
antibodi
level
howev
postul
highli
vaccin
popul
lack
exposur
natur
varicella
may
result
wane
immun
adolesc
adult
two
dose
week
apart
necessari
produc
seroconvers
rate
antibodi
respons
similar
obtain
healthi
children
varicellazost
vaccin
recommend
suscept
adult
particularli
highrisk
situat
ie
healthcar
personnel
children
histori
chickenpox
requir
attend
school
immunosuppress
individu
particularli
acut
lymphocyt
leukaemia
vzv
vaccin
safe
administ
patient
patient
lymphocyt
count
two
dose
separ
month
given
individu
sinc
immun
respons
provid
protect
seroconvers
rate
one
dose
vaccin
rash
develop
vaccine
varicella
transmiss
occur
onefourth
rate
natur
varicella
vs
incid
per
person
year
followup
children
herp
zoster
later
develop
either
vaccinetyp
viru
natur
wildtyp
vzv
incid
less
seen
children
prior
chickenpox
vaccin
children
may
decreas
risk
herp
zoster
modifi
varicellalik
syndrom
mvl
may
occur
vaccin
children
exposur
natur
wildtyp
varicella
viru
averag
rate
mvl
vari
vaccin
children
year
vaccin
us
licens
oka
strain
vaccin
children
typic
develop
milder
form
diseas
children
associ
fever
develop
vesicular
lesion
typic
lesion
children
mvl
shown
associ
system
seriou
diseas
children
develop
mvl
often
develop
complet
longerlast
antibodi
respons
varicella
vaccin
advers
effect
oka
vaccin
gener
well
toler
common
side
effect
children
adult
includ
mild
tender
erythema
indur
inject
site
fever
local
gener
varicellalik
rash
transmiss
varicella
vaccin
viru
healthi
vaccine
low
may
like
rash
develop
vaccin
especi
among
immunocompromis
individu
receiv
vaccin
avoid
close
associ
suscept
highrisk
individu
week
vaccin
contraind
pregnanc
woman
plan
becom
pregnant
within
month
sinc
live
attenu
viru
natur
varicella
known
caus
fetal
harm
recent
data
indic
varicella
vaccin
effect
prevent
diseas
prevent
moder
sever
diseas
suscept
contact
given
within
h
exposur
vaccin
avail
end
centuri
use
sole
prevent
diseas
fda
approv
viral
vaccin
remov
market
safeti
issu
rotaviru
vaccin
also
new
candid
vaccin
develop
evalu
treatment
alreadi
acquir
viral
infect
tabl
list
predomin
diseas
candid
vaccin
present
investig
adenoviru
common
caus
signific
respiratori
ill
militari
group
immun
thu
indic
us
militari
popul
adenoviru
also
caus
pneumonia
hospit
children
well
gastroenter
infant
children
although
immun
recommend
popul
vaccin
approv
avail
live
oral
entericco
tablet
avail
two
differ
strainstyp
type
adenoviru
vaccin
sever
studi
vaccin
recipi
demonstr
signific
decreas
reduct
acut
respiratori
diseas
due
adenoviru
unfortun
product
vaccin
discontinu
depart
defens
current
search
altern
sourc
product
rotaviru
caus
million
case
diarrhoea
annual
children
less
year
age
approxim
death
worldwid
us
rotaviru
respons
approxim
hospit
death
year
rhesushuman
reassort
tetraval
rrvtv
rotaviru
vaccin
rotashield
licens
use
us
oral
vaccin
consist
live
attenu
rhesu
rotaviru
serotyp
humanrhesu
reassort
express
serotyp
clinic
trial
three
dose
rotaviru
vaccin
result
efficaci
diseas
vaccin
also
prevent
dehydr
recipi
reduc
physician
visit
twenti
percent
infant
develop
fever
rotaviru
vaccin
gener
day
first
dose
older
infant
higher
incid
febril
reaction
restrict
use
vaccin
first
month
life
irrit
decreas
appetit
activ
report
advers
effect
trial
rotaviru
vaccin
fdaapprov
administr
three
dose
month
age
soon
public
avail
vaccin
sever
case
intussuscept
vaccine
report
approxim
case
per
infantyear
compar
case
per
infantyear
unvaccin
infant
accord
vaccin
advers
event
report
system
major
infant
develop
complic
first
vaccin
dose
develop
symptom
within
week
immun
concern
possibl
associ
rhesusbas
rotaviru
vaccin
intussuscept
cdc
recommend
postpon
rotaviru
vaccin
studi
complet
vaccin
longer
avail
anoth
humananim
reassort
vaccin
undergo
clinic
trial
base
bovin
rotaviru
parent
strain
thu
far
prove
safe
effect
differ
live
rotaviru
vaccin
also
shown
promis
efficaci
rate
phase
ii
clinic
trial
human
rotaviru
vaccin
live
attenu
strain
deriv
fecal
specimen
rotavirusinfect
child
cincinnati
ohio
vaccin
effect
prevent
diseas
infant
two
dose
serolog
evid
immun
demonstr
recipi
mild
fever
advers
reaction
experienc
date
infect
herp
simplex
viru
cosmet
disfigur
substanti
morbid
mortal
herp
simplex
viru
hsv
vaccin
sought
past
eight
decad
initi
studi
unsuccess
use
untreat
vesicular
fluid
herp
lesion
attempt
induc
immun
inactiv
whole
viru
vaccin
made
hsvinfect
anim
tissu
develop
mani
inactiv
whole
viru
vaccin
develop
past
year
none
candid
vaccin
prove
suffici
immunogen
sever
approach
hsv
vaccin
current
develop
evalu
two
recombin
subunit
vaccin
investig
phase
iii
trial
vaccin
develop
chiron
contain
surfac
glycoprotein
gb
gd
adjuv
vaccin
provid
protect
efficaci
prevent
therapeut
use
develop
vaccin
subsequ
halt
recombin
vaccin
develop
smithklin
beecham
contain
glycoprotein
gd
adjuv
monophosphoryl
lipid
immunostimul
mpl
clinic
trial
vaccin
clinic
efficaci
protect
women
serolog
neg
acquir
diseas
two
multicent
doubleblind
random
control
studi
glycoproteindsubunit
vaccin
formul
new
adjuv
contain
aluminum
hydroxid
alum
mpl
prevent
genit
herp
shown
efficaci
subgroup
analysi
first
studi
phase
doubleblind
random
efficaci
trial
involv
random
subject
seroneg
second
studi
phase
doubleblind
random
trial
design
evalu
safeti
vaccin
subject
hsv
serolog
statu
studi
random
patient
seroneg
neg
women
studi
efficaci
vaccin
confid
interv
case
occur
vaccin
group
control
group
studi
efficaci
femal
subject
confid
interv
nine
case
occur
vaccin
group
control
group
howev
women
seroneg
efficaci
studi
confid
interv
p
efficaci
studi
confid
interv
p
vaccin
shown
effect
women
seroposit
men
efficaci
differ
women
men
may
explain
biolog
immunolog
factor
acquisit
hsv
women
like
occur
vaginalcerv
mucou
membran
stratum
corneum
secret
constantli
wash
membran
contain
antibodi
white
blood
cell
vaccin
could
provid
immunolog
barrier
hsv
acquisit
mucos
site
applic
men
evid
autoimmun
disord
infect
vaccin
femal
subject
human
anim
enhanc
immun
respons
type
helper
cell
compar
male
subject
respons
especi
interferonsecret
shown
import
control
hsv
infect
glycoproteindsubunit
vaccin
studi
phase
iii
doubleblind
random
control
trial
sponsor
glaxosmithklin
nation
institut
health
enrol
goal
women
seroneg
receiv
investig
herp
vaccin
investig
formul
schedul
havrix
given
dose
schedul
month
primari
endpoint
evalu
vaccin
efficaci
prevent
genit
herp
caus
either
month
post
second
dose
healthi
women
initi
seroneg
march
women
enrol
case
genit
herp
report
anoth
approach
combin
safeti
profil
kill
vaccin
immunogen
potenti
live
viru
vaccin
disabl
infecti
singl
cycl
disc
vaccin
lack
glycoprotein
h
gh
gene
necessari
viru
entri
cell
thu
herp
simplex
viru
unabl
spread
surround
cell
singl
replic
cycl
essenti
remain
noninfecti
anim
studi
approach
provid
encourag
result
prevent
therapeut
treatment
howev
candid
vaccin
fail
phase
ii
trial
clinic
trial
vaccin
plan
evalu
efficaci
prevent
infect
seroneg
partner
discord
coupl
dna
vaccin
also
studi
potenti
hsv
immun
vaccin
abl
express
viral
antigen
time
absenc
adjuv
strong
cellmedi
immun
induc
anim
studi
inocul
plasmid
dna
carri
desir
viral
gene
shown
promis
result
prevent
infect
dna
vaccin
encod
glycoprotein
current
phase
clinic
trial
sever
other
preclin
develop
live
attenu
hsv
vaccin
also
attempt
virus
safest
attenu
tend
lack
immunogen
therefor
caus
difficulti
develop
vaccin
past
research
shown
stabl
attenu
hsv
achiev
passag
cell
cultur
vaccin
strain
potenti
revert
virul
state
caus
diseas
immun
genet
engin
hsv
mutant
vaccin
found
safe
effect
anim
studi
human
strain
overli
attenu
lack
suffici
immunogen
subtyp
human
papillomaviru
hpv
known
sexual
transmitt
certain
subtyp
associ
malign
subtyp
associ
condylomata
subtyp
allow
focus
strategi
immun
past
vaccin
develop
hamper
due
inabl
cultur
hpv
vitro
cultur
system
hpv
develop
further
prospect
advanc
field
viruslik
particl
vlp
design
selfassembl
conform
resembl
natur
hpv
vlp
design
major
hpv
subtyp
clinic
trial
underway
vlp
vlp
vlp
doubleblind
placebo
control
studi
individu
neg
receiv
vaccin
reduc
incid
infect
relat
cervic
intraepitheli
neoplasia
median
followup
month
fusion
protein
vaccin
evalu
immunotherapi
cervic
cancer
genit
wart
live
recombin
vaccinia
viru
tahpv
engin
express
protein
gene
hpv
treatment
cervic
cancer
vaccinia
viru
serv
viral
vector
vaccin
phase
ii
clinic
trial
tahpv
provid
encourag
result
studi
underway
recombin
fusion
protein
vaccin
tagw
consist
protein
investig
treatment
genit
wart
phase
ii
clinic
trial
shown
vaccin
immunogen
encourag
clinic
respons
third
fusion
protein
vaccin
tacin
preclin
develop
treatment
cervic
dysplasia
although
tcell
repertoir
mice
human
differ
peptidebas
vaccin
shown
protect
hpvinduc
tumor
mice
earlystag
human
clinic
trial
underway
one
clinic
trial
involv
hlaa
bind
peptid
investig
approach
hpv
immun
includ
dna
vaccin
bacteri
vector
dendrit
cell
puls
hpv
epitop
respiratori
syncyti
viru
rsv
common
caus
sever
lower
respiratori
tract
infect
infant
young
children
result
approxim
hospit
death
us
year
earli
attempt
vaccin
develop
thwart
clinic
trial
formalininactiv
vaccin
led
sever
unexpect
ill
upon
subsequ
natur
rsv
infect
sinc
time
multipl
vaccin
approach
evalu
mani
concern
use
inactiv
rsv
vaccin
first
rsv
vaccin
test
intramuscular
formalininactiv
aluminumprecipit
vaccin
children
less
year
age
observ
administr
vaccin
subsequ
natur
infect
rsv
associ
sever
respiratori
diseas
wide
accept
theori
phenomena
imbal
occur
lymphocyt
respons
vaccin
mice
immun
formalininactiv
rsv
vaccin
pulmonari
histolog
find
consist
respons
ineffect
immun
respons
rsv
due
past
event
formalininactiv
rsv
vaccin
inactiv
rsv
vaccin
research
licens
vaccin
prevent
rsv
signific
progress
live
attenu
rsv
vaccin
candid
sever
live
attenu
coldpassag
temperaturesensit
cpt
rsv
mutant
evalu
rsvnaiv
infant
seroposit
children
healthi
adult
adult
rsvseroposit
children
cpt
cpt
cpt
mutant
shown
safe
howev
cpt
mutant
underattenu
young
infant
henc
suffici
safe
vaccin
candid
proceed
vaccin
trial
infant
infant
cpt
cpt
mutant
produc
prolong
viral
replic
insuffici
attenu
viru
transmit
almost
quarter
placebo
recipi
cpt
vaccin
associ
increas
frequenc
upper
respiratori
symptom
littl
evid
lower
respiratori
ill
howev
reduct
reinfect
second
dose
impli
first
dose
somewhat
protect
recent
develop
revers
genet
technolog
allow
genet
engin
mutant
viru
rabcp
sh
recent
evalu
infant
appear
promis
vaccin
candid
live
attenu
vaccin
rsv
advantag
intranas
administr
potenti
protect
upper
lower
respiratori
tract
diseas
earli
trial
coldpassag
strain
demonstr
poor
infect
immunogen
research
provid
improv
coldpassag
temperaturesensit
mutant
one
particular
candid
cpt
shown
safe
immunogen
children
older
month
led
nasal
congest
infant
month
age
addit
live
attenu
vaccin
candid
current
evalu
anim
model
promis
result
advanc
technolog
may
also
provid
improv
live
attenu
vaccin
genet
engin
subunit
vaccin
consist
purifi
rsv
glycoprotein
promis
candid
rsv
immun
two
separ
purifi
f
subunit
protein
vaccin
shown
safe
immunogen
clinic
trial
involv
healthi
adult
elderli
subject
rsvseroposit
children
month
age
children
pulmonari
diseas
clinic
studi
includ
subunit
vaccin
g
protein
fragment
rsva
plan
human
parainfluenza
viru
piv
type
infect
second
common
caus
seriou
respiratori
tract
diseas
infant
children
rsv
year
approxim
children
year
age
experi
clinic
signific
piv
infect
requir
hospit
viru
subtyp
commonli
caus
bronchopneumonia
bronchiol
young
children
two
separ
live
attenu
vaccin
evalu
coldpassag
cp
vaccin
coldadapt
temperaturesensit
prospect
earli
studi
strain
suffici
attenu
children
strain
show
promis
result
strain
given
intranas
children
vaccin
candid
found
immunogen
safe
antigenicallyrel
bovin
vaccin
also
evalu
earli
clinic
trial
result
indic
vaccin
safe
immunogen
poorli
transmitt
addit
serum
hemagglutinationinhibit
antibodi
respons
increas
compar
induc
coldpassag
trival
subunit
vaccin
well
recombin
vaccin
also
evalu
potenti
parainfluenza
vaccin
candid
although
cytomegaloviru
cmv
produc
uncommon
mononucleosislik
syndrom
immunocompet
patient
potenti
effect
newborn
immunocompromis
patient
devast
congenit
cmv
common
intrauterin
infect
us
estim
american
infant
develop
neurolog
fatal
complic
year
diseas
sever
type
cmv
vaccin
evalu
first
live
attenu
town
strain
vaccin
first
develop
clinic
studi
seroneg
renal
allograft
recipi
show
vaccin
prevent
infect
significantli
reduc
incid
sever
diseas
approxim
anoth
studi
evalu
effect
cmv
vaccin
prevent
childtomoth
transmiss
cmv
acquir
daycar
centr
infect
rate
vaccin
mother
differ
placebo
natur
seroposit
mother
protect
disappoint
result
show
town
strain
vaccin
induc
immun
effect
natur
infect
work
underway
develop
improv
version
town
strain
vaccin
subunit
glycoprotein
b
gb
vaccin
also
evalu
cmv
immun
clinic
studi
vaccin
healthi
toddler
adult
shown
good
immun
respons
neutral
antibodi
rapidli
declin
month
follow
third
dose
fourth
dose
adult
led
higher
antibodi
level
though
titer
declin
month
longterm
data
studi
yet
avail
clinic
vaccin
efficaci
studi
mother
underway
evalu
effect
antibodi
respons
canarypoxgb
recombin
vaccin
develop
evalu
candid
cmv
vaccin
initi
trial
demonstr
weak
antibodi
respons
multipl
dose
addit
studi
current
evalu
potenti
primer
boost
subsequ
town
strain
inject
potenti
hope
avenu
cmv
vaccin
includ
dna
plasmid
hla
restrict
peptidebas
vaccin
develop
effect
hiv
vaccin
critic
million
peopl
infect
die
worldwid
current
hiv
vaccin
candid
report
research
develop
preclin
test
anim
sinc
least
differ
hiv
candid
vaccin
begun
phase
trial
progress
phase
ii
trial
vaxgen
aid
product
aidsvax
recombin
gp
subunit
vaccin
advanc
phase
iii
trial
fail
potenti
obstacl
success
develop
effect
hiv
vaccin
genet
variat
specif
envelop
protein
recombin
subunit
hiv
vaccin
genet
engin
hiv
surfac
envelop
protein
vaccin
contain
live
viru
dna
therapeut
studi
use
subunit
administ
everi
month
year
demonstr
modest
effect
count
clinic
benefit
hiv
posit
person
take
antiretrovir
therapi
viru
vector
genet
engin
express
certain
hiv
gene
vaccinia
viru
first
recombin
liveviru
vector
test
hiv
gene
insert
vaccina
viru
genom
vaccin
alon
stimul
much
antibodi
product
howev
vaccin
follow
boost
recombin
vaccin
induc
strong
cellular
immun
antibodi
respons
remain
determin
candid
vaccin
abl
prevent
infect
seroneg
individu
safeti
immunogen
combin
recombin
subtyp
e
b
hiv
type
envelop
vaccin
test
seriou
advers
event
found
relat
vaccin
lymphoprolif
respons
bind
antibodi
found
vaccin
recipi
potenti
viral
vector
includ
canarypox
adenoviru
unlik
vaccinia
viru
canarypox
adenoviru
infect
human
replic
import
sinc
vaccinia
viru
shed
possibl
dissemin
immunosuppress
host
canarypox
adenoviru
produc
necessari
hiv
protein
termin
replic
canarypox
vector
abl
induc
humor
cellular
immun
respons
februari
trial
commenc
uganda
use
canarypox
vector
vaccin
alvac
vaccin
contain
three
hiv
gene
clade
b
virus
clade
b
viru
predomin
subtyp
hiv
found
us
europ
uganda
common
subtyp
hiv
clade
studi
evalu
crossreact
among
viral
subunit
compar
immun
respons
recipi
canarypox
vaccin
greatest
potenti
lie
prime
boost
approach
initi
canarypox
vaccin
primer
abl
induc
strong
cellular
immun
primer
follow
recombin
subunit
vaccin
boost
antibodi
respons
combin
primer
follow
boost
induc
stronger
immun
respons
either
one
alon
result
phase
ii
trial
show
subject
receiv
combin
vaccin
develop
neutral
antibodi
onethird
develop
hivspecif
cytotox
tlymphocyt
respons
broader
recombin
vector
vaccin
would
like
increas
percentag
respond
dna
nucleic
acid
vaccin
anoth
potenti
prospect
hiv
immun
purifi
dna
encod
particular
immunogen
antigen
inject
vaccin
recipi
antigen
present
host
immun
system
nativ
form
process
similar
natur
viral
infect
therapeut
immun
plasmid
gag
pol
dna
vaccin
hivposit
chimpanze
produc
signific
decreas
viral
load
boost
immun
respons
seroneg
primat
studi
show
induct
neutral
antibodi
cytotox
tlymphocyt
respons
howev
vaccin
protect
hiv
infect
two
dna
vaccin
candid
current
phase
trial
potenti
prospect
hiv
vaccin
develop
investig
anim
model
liveattenu
hiv
vaccin
abl
gener
broad
durabl
immun
respons
due
potenti
safeti
concern
live
hiv
viru
vaccin
test
human
wholeinactiv
vaccin
use
chimpanze
inactiv
viru
often
lead
vaccin
less
potent
immunogen
without
provid
protect
hiv
infect
risk
incomplet
inactiv
could
lead
hiv
infect
vaccin
recipi
viruslik
particl
vlp
also
attempt
provid
safer
option
sinc
consist
noninfecti
hiv
lookalik
contain
hiv
genom
earli
result
shown
vlp
candid
known
ty
lead
low
level
hiv
bind
antibodi
tcell
memori
respons
induc
littl
cytotox
tlymphocyt
activ
vlp
candid
research
develop
result
clinic
trial
avail
near
futur
vaccin
sever
viral
diseas
current
earli
stage
develop
least
four
differ
type
hepat
c
vaccin
preclin
develop
howev
research
candid
vaccin
hamper
lack
reproduc
tissu
cultur
conveni
small
anim
model
test
defin
constitut
protect
immun
respons
role
antibodi
hepat
c
viru
serv
earli
studi
chimpanze
sever
hepat
c
vaccin
current
underway
three
differ
epstein
barr
viru
vaccin
type
report
phase
studi
includ
glycoprotein
subunit
vaccin
vaccinia
recombin
vaccin
express
peptid
induct
cutan
lymphocyt
unknown
specif
antigen
compon
vaccin
suffici
prevent
infect
least
differ
vaccin
develop
dengu
viru
preclin
stage
live
attenu
monoval
vaccin
phase
iii
clinic
trial
combin
quadrival
vaccin
phase
trial
liveattenu
vaccin
shown
promis
prevent
infect
ebola
vaccin
recent
develop
experiment
vaccin
shown
success
protect
nonhuman
primat
ebola
diseas
gener
ebolaspecif
cell
antibodi
respons
month
howev
requir
complet
immun
nonhuman
primat
test
potenti
west
nile
viru
wnv
vaccin
includ
formalininactiv
nake
dna
live
attenu
recombin
virus
molecular
liveattenu
live
attenu
recombin
vaccin
chimerivax
appear
promis
wnv
vaccin
candid
molecular
liveattenu
wnv
vaccin
genet
engin
bear
membran
precursor
envelop
protein
gene
wnv
backbon
dengu
viru
anim
studi
wnden
induc
moderatetohigh
titer
neutral
antibodi
prevent
viremia
monkey
challeng
wnv
chimerivax
replac
gene
encod
premembran
prm
envelop
e
protein
yellow
fever
vaccin
envelop
gene
wnv
result
virion
replic
host
like
yellow
fever
viru
allow
immun
specif
wnv
anim
studi
vaccin
induc
high
humor
antibodi
respons
human
clinic
trial
underway
wnv
vaccin
sever
acut
respiratori
syndrom
sar
acceler
vaccin
initi
savi
develop
test
three
potenti
sar
vaccin
anim
anim
model
ie
mice
vaccin
induc
broad
immun
viru
specif
structur
sarsassoci
coronaviru
antigen
spike
protein
fragment
membran
protein
nucelocapsid
protein
result
studi
avail
year
possibl
test
china
vaccin
work
earli
adenovir
deliveri
codonoptimis
sarscov
strain
antigen
shown
induc
virusspecif
broad
immun
rhesu
monkey
potenti
sar
vaccin
util
inactiv
viru
dna
encod
outer
surfac
protein
sar
viru
immun
success
reduc
incid
numer
diseas
care
develop
clinic
evalu
provid
safe
effect
vaccin
advers
effect
mani
report
advers
reaction
follow
vaccin
might
coincident
proven
direct
relationship
vaccin
question
although
seriou
side
effect
may
occur
vaccin
much
greater
risk
morbid
mortal
result
failur
becom
immun
one
vaccin
recent
remov
market
due
safeti
issu
rotashield
live
oral
tetraval
rotaviru
vaccin
associ
sever
case
intussuscept
consid
causal
associ
vaccin
advers
event
demonstr
causal
exampl
measl
mump
rubella
mmr
vaccin
report
causal
relationship
autism
nevertheless
suspect
relationship
vaccin
advers
event
need
report
vaccin
advers
event
report
system
excel
safeti
record
vaccin
maintain
technolog
vaccin
develop
progress
dramat
last
decad
convent
method
consist
wholekil
live
attenu
virus
recent
advanc
includ
genet
engin
vector
viruslik
particl
anticip
vaccin
develop
futur
show
excit
promis
sever
area
immun
plant
potato
tomato
banana
current
undergo
genet
engin
express
immun
antigen
infect
form
vaccin
would
offer
conveni
painless
inexpens
approach
widespread
control
diseas
would
thu
access
develop
countri
anticip
futur
bring
safe
effect
vaccin
varieti
viral
diseas
constantli
continu
expand
concept
vaccin
ongo
experiment
clinic
trial
therapeut
vaccin
